Xenografts can grow in immunosuppressed hosts, such as SCID mice, and tumor material can be injected into hosts either ectopically or orthotopically. Choosing the correct model to use is a crucial step in animal research. The aim of this study was to report the differences between ectopic and orthotopic xenografts in tumor progression, metastasis capacity, histological features, and steroid hormone profiles in xenografts from the cIMC (canine inflammatory mammary cancer) cell line IPC-366 and hIBC (human inflammatory breast cancer) cell line SUM149. To achieve this purpose, 40 female mice 6-8 weeks old were inoculated with IPC-366 and SUM149 cells subcutaneously (ectopic models) or into mammary fat pad (orthotopic models). Mice were monitored for tumor progression and appearance of metastases, and generated tumors were analyzed in terms of histological examination and steroid hormone production. The results revealed differences in tumor appearance and percentage of metastasis between ectopic and orthotopic models, which were higher in the ectopic xenografts from both cell lines. However, both models had similar characteristics of tumor progression, histological features, and steroid hormone secretion profiles. We show that the ectopic model can be validated as a good and useful model of tumor development in addition to, not contrary to, the orthotopic model in breast cancer research.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470891 | PMC |
| http://dx.doi.org/10.3390/vetsci8090194 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ectopic olfactory neuroblastoma is associated with increased frequency of syndrome of inappropriate antidiuretic hormone secretion and reduced disease control: Case series with systematic review and pooled analysis.
Int Forum Allergy Rhinol
January 2025
Section of Otorhinolaryngology-Head and Neck Surgery, Department of Neuroscience, University of Padova, Padova, Italy.
Introduction: Olfactory neuroblastoma (ONB) is a rare malignant tumor originating from the olfactory neuroepithelium, typically within the sinonasal cavity. Cases of ONB originating outside of the olfactory cleft area are extremely rare and are referred to as "ectopic" (eONB), in contrast to "orthotopic" tumors (oONB). ONB has been associated with paraneoplastic syndromes (PNSs), including the syndrome of inappropriate antidiuretic hormone secretion (SIADH).
View Article and Find Full Text PDFDo not Judge a book by its Cover: A Secretory Carcinoma Arising from a Salivary Gland Heterotopia in Laterocervical lymph-node.
Head Neck Pathol
October 2024
Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum, Unit of Anatomic Pathology, University of Bologna, Bellaria Hospital, Bologna, Italy.
Article Synopsis
- Heterotopia refers to the abnormal presence of salivary gland tissue in atypical locations during development, and malignant growths from these ectopic tissues are uncommon.
- A case study detailed a 66-year-old male with a neck mass, initially thought to be benign, which was later diagnosed as Secretory Carcinoma (SC) arising from heterotopic salivary gland tissue within a lymph node after surgical removal.
- This case is particularly significant as it highlights the rare occurrence of SC in heterotopic tissues, enhancing knowledge of how tumors in unusual sites behave similarly to those in normal salivary glands.
Frequency and characteristics of ectopic parathyroid adenomas in a cohort of patients referred for 18 F-fluorocholine PET/CT.
Nucl Med Commun
January 2025
Department of Nuclear Medicine, Northwest Clinics, Alkmaar.
Aim: This article aimed to study the frequency and characteristics of ectopic/intrathyroidal parathyroid adenomas in patients referred for 18 F-fluorocholine PET/computed tomography (CT).
Patients And Methods: From 11 June 2015 to 15 January 2024, 729 patients were studied. Recorded patient variables included hyperparathyroidism type, sex, age, presence of symptoms, renal involvement, bone involvement, parathyroid hormone (PTH), and serum calcium, phosphate, and vitamin D as well as 24-h urine calcium excretion.
CD81-guided heterologous EVs present heterogeneous interactions with breast cancer cells.
J Biomed Sci
October 2024
Laboratory of Biotechnology and Nanomedicine, Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123, Trento, Italy.
Background: Extracellular vesicles (EVs) are cell-secreted particles conceived as natural vehicles for intercellular communication. The capacity to entrap heterogeneous molecular cargoes and target specific cell populations through EV functionalization promises advancements in biomedical applications. However, the efficiency of the obtained EVs, the contribution of cell-exposed receptors to EV interactions, and the predictability of functional cargo release with potential sharing of high molecular weight recombinant mRNAs are crucial for advancing heterologous EVs in targeted therapy applications.
View Article and Find Full Text PDFZelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells.
Mol Cancer Ther
January 2025
Department of Cell Biology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Canada.
Article Synopsis
- Acute myeloid leukemia (AML) is a serious blood cancer with few treatment options and a high chance of coming back after chemotherapy.
- Researchers studied N-myristoylation, a protein modification linked to cancer cell survival, and found that the level of N-myristoyltransferase 2 (NMT2) can indicate patient outcomes.
- They tested a drug called zelenirstat, which inhibits myristoylation, and found it caused cancer cell death and reduced leukemia in models, suggesting it could be an effective new treatment for AML patients with poor prognoses.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!